MedTrace Logo

Genomic Landscape of Ceritinib

NCT02554591 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2018-03-05

No results posted yet for this study

Summary

The investigators propose to conduct a retrospective study of single agent ceritinib in patients with previously untreated anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma of the lung with the sole purpose of characterizing the genomic landscape before ceritinib and at the time of disease progression.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Ramaswamy Govindan, M.D. · Washington University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-16
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02554591 on ClinicalTrials.gov